Nimodipine Altan

Nimodipine, the active ingredient in Nimodipine Altan, is a calcium channel blocker presented as an intravenous solution for intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage, helping to maintain adequate cerebral blood flow in affected patients.

GNH USA supplies Nimodipine Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Nimodipine is used in the management of cerebrovascular complications, particularly those related to subarachnoid hemorrhage.

Aneurysmal subarachnoid hemorrhage: prevents delayed cerebral vasospasm and reduces risk of ischemic complications. Delayed cerebral ischemia after SAH: lowers incidence of secondary brain injury. Cerebral blood flow impairment post‑SAH: supports perfusion to vulnerable brain tissue.

Nimodipine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypotension: reduced blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and redness of skin. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Myocardial infarction: rare cardiac ischemic events. - Arrhythmias: abnormal heart rhythms, including bradycardia. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Seizures: infrequent neurologic events.

When prescribing Nimodipine, clinicians should consider several precautionary measures to ensure safe use.

Blood pressure monitoring: check for hypotension before and during therapy. Cardiac function assessment: evaluate for existing heart block or ischemia. Liver function: monitor enzymes in patients with hepatic impairment. Concomitant vasodilators: avoid additive hypotensive effects. Pregnancy and lactation: use only if benefits outweigh risks. Store below 25°C: keep in the original pack, protect from moisture and light.

Nimodipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels leading to toxicity. - Potent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Beta‑blockers: may exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance hypotensive effect. - Antihypertensive agents: dose adjustment may be required.